“I appreciate this honor, and look forward to the efforts of my colleagues at Muses Labs to finally put an end to the suffering and crippling effects that Alzheimer’s disease has on patients and their loved ones.”
Research Triangle Park, NC (PRWEB) December 09, 2013
Dale Bredesen, MD, co-founder of North Carolina-based Muses Labs, Inc., has been awarded the 2013 Turken International Lecture Award. The award, hosted by the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, is given annually to a distinguished expert in the field of Alzheimer’s research.
In Los Angeles to receive the award, Bredesen stated, “I appreciate this honor, and look forward to the efforts of my colleagues at Muses Labs to finally put an end to the suffering and crippling effects that Alzheimer’s disease has on patients and their loved ones.”
Dr. Bredesen is the Chief Medical Officer for Muses Labs, a software company focused on combining the latest scientific findings, big-data analytics and algorithms into creating personalized treatments for Alzheimer’s disease.
“This is an exciting time to be doing Alzheimer’s research,” Bredesen noted. “We finally have the computing power to deeply analyze the various medical factors underlying the root causes of Alzheimer’s disease. Now that we can see all that data, our software lets physicians tailor an Alzheimer’s therapy to the exact set of circumstances and symptoms a patient is experiencing,” he added.
Dr. Bredesen is using an early version of the software to work with patients at the Buck Institute for Research on Aging. The personalized therapy is data driven; it relies on genomic data, bio-specimens such as blood tests, as well as brain scans and other markers that indicate the specific imbalances to be corrected in an individual. Dozens of medical factors are analyzed so that they may be brought into balance. The software recommends a prioritized plan that provides an achievable path to prevention and recovery. The software infrastructure also helps patients comply with their therapy. Using Muses Labs’ software, patients work with their physicians and caregivers to return to normal lives.
About Dr. Bredesen:
Dr. Bredesen is the Chief Medical Officer for Muses Labs, and maintains his position as director of the Bredesen Lab at the Buck Institute for Research on Aging. He is internationally recognized as an expert in the mechanisms of neurodegenerative diseases and dementia. He graduated from Caltech, and earned his MD from Duke University in Durham, North Carolina. Dr. Bredesen served as Chief Resident in Neurology at the University of California, San Francisco (UCSF) before joining Nobel-laureate Stanley Prusiner’s laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA, and the University of California, San Diego. Dr. Bredesen directed the Program on Aging at the Burnham Institute before coming to the Buck Institute for Research on Aging in 1998, as its founding President and CEO.
About the Turken International Awards:
In 1991, Phyllis Turken Shamberg initiated a gift to support the early career of UCLA researchers interested in studying Alzheimer’s disease. In addition to research, the annual gift also supports invitation of a distinguished "Turken International Lecturer" as part of the award events each year.
About Muses Labs
Founded in 2013, Muses Labs, Inc. is headquartered in Research Triangle Park, North Carolina. Muses Labs creates software that takes a systems approach to prevention and recovery for Alzheimer's patients. Based on 30 years of medical research from around the world, the software implements a protocol developed by Dr. Dale E. Bredesen to deliver a data-driven personalized therapy recommendation for Alzheimer's patients and those interested in preventing it.
For more information on Muses Labs' work, visit http://www.museslabs.com.